MedTrace Logo

Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

NCT02441972 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-03-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.

Conditions

  • Tumors
  • Carcinoma, Bronchogenic
  • Breast Carcinoma
  • Cancer of Head and Neck
  • Lymphoma, Malignant
  • Soft Tissue Neoplasms

Interventions

DRUG

18F-Al-NOTA-PRGD2 PET/CT

18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

Sponsors & Collaborators

  • Wuxi No. 4 People's Hospital

    lead OTHER

Principal Investigators

  • Weixing Wan, Professor · Wuxi No. 4 People's Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02441972 on ClinicalTrials.gov